Aurora Cannabis Inc.
ACB Healthcare Drug Manufacturers Specialty & Generic
Aurora Cannabis Inc.’s revenue for fiscal 2026 (year ended March 2026) was $232.0 million, down 5.95% from fiscal 2025. In the quarter to June 2026, revenue fell 31.2%, EPS grew 75.0%, free cash flow fell 293.6% and total debt fell 82.5%, each against the same quarter a year earlier.
Follow ACB
Aurora Cannabis Inc. (ACB) EV/Sales
As of 16 October 2026, Aurora Cannabis Inc. (ACB) trades at a EV/Sales of 0.9×. Over the past ten years it has ranged from 0.0× (March 2017) to 1,038× (September 2018); the current reading is higher than 30% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 2.7× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2026 | 0.5× | (26.30%) |
| FY2025 | 0.7× | 16.36% |
| FY2024 | 0.6× | (11.93%) |
| FY2023 | 0.7× | (95.36%) |
| FY2022 | 15.2× | (80.92%) |
| FY2021 | 79.6× | 34.81% |
| FY2020 | 59.1× | (86.12%) |
| FY2019 | 426× | (42.64%) |
| FY2018 | 742× | 128.88% |
| FY2017 | 324× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.6× | 7.97% |
| Mar 2026 | 0.5× | (27.53%) |
| Dec 2025 | 0.7× | (36.05%) |
| Sep 2025 | 1.2× | 70.15% |
| 37 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BIOA BioAge Labs, Inc. compare | −9.7× |
| AKBA Akebia Therapeutics, Inc. compare | 0.3× |
| ACB Aurora Cannabis Inc. | 0.9× |
| EBS Emergent Biosolutions Inc. compare | 1.0× |
| CGC Canopy Growth Corporation compare | 1.1× |
| ANIK Anika Therapeutics Inc. compare | 2.1× |
| LFCR Lifecore Biomedical, Inc. compare | 3.4× |
| SIGA Siga Technologies Inc. compare | 5.0× |
| TKNO Alpha Teknova, Inc. compare | 8.7× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)